Abstract
The prognosis of patients with relapsed/refractory peripheral T-cell lymphoma (PTCL) remains poor and current treatments are typically of limited benefit. Histone deacetylase (HDAC) inhibitors have proven effective for the treatment of relapsed/refractory PTCL. To date approved HDAC inhibitors for patients with T-cell lymphoma are vorinostat, romidepsin and, recently, belinostat. Here we review the pharmacology and the clinical activity of belinostat. Belinostat is a well-tolerated HDAC inhibitor that has shown activity in heavily pretreated patients with relapsed/refractory PTCL. Several clinical trials are currently investigating the use of belinostat in different cancers and in combination with other chemotherapeutic agents.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1659-1664 |
| Number of pages | 6 |
| Journal | Future Oncology |
| Volume | 11 |
| Issue number | 11 |
| DOIs | |
| State | Published - Jun 1 2015 |
Bibliographical note
Publisher Copyright:© 2015 Future Medicine Ltd.
Keywords
- T-cell lymphoma
- belinostat
- histone deacetylase inhibitor
